Who
Zoran Zdraveski
Officer
Company insider
Files Form 4 as: Chief Legal Officer, TScan Therapeutics; Officer, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 1
- Sells
- 5
- Bought
- $35K
- Sold
- $1.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Jun 2018
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 3 Jan 2025filed 11 Feb 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —54,895 at $0.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,125 at $0.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,166 at $0.00 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code M | $266K54,895 at $4.85 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code M | $82K25,000 at $3.27 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code M | $24K13,125 at $1.81 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code M | $160K64,166 at $2.49 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Sold | $952K164,686 at $5.78 | filing |
| 12 Jan 2024filed 11 Feb 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —430,000 at $0.00 | filing |
| 2 Feb 2023filed 6 Feb 2023 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jul 2022filed 27 Jul 2022 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 23 Sep 2021filed 27 Sep 2021 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $35K4,716 at $7.48 | filing |
| 7 Sep 2021filed 9 Sep 2021 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyTCRX · themarketsdaily.com · 20 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Zoran Zdraveski; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.